0001213900-17-010345.txt : 20171006 0001213900-17-010345.hdr.sgml : 20171006 20171006101843 ACCESSION NUMBER: 0001213900-17-010345 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20171006 DATE AS OF CHANGE: 20171006 EFFECTIVENESS DATE: 20171006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RELMADA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001553643 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455401931 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-296142 FILM NUMBER: 171125981 BUSINESS ADDRESS: STREET 1: 275 MADISON AVENUE, SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 646-677-3853 MAIL ADDRESS: STREET 1: 275 MADISON AVENUE, SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: CAMP NINE, INC. DATE OF NAME CHANGE: 20120706 D 1 primary_doc.xml X0708 D LIVE 0001553643 RELMADA THERAPEUTICS, INC. 750 THIRD AVENUE 9TH FLOOR NEW YORK NY NEW YORK 10017 212-547-9591 NEVADA Camp Nine, Inc. CAMP NINE, INC. Corporation true Sergio Traversa 750 Third Avenue 9th Floor New York NY NEW YORK 10017 Executive Officer Director Charles Casamento 750 Third Avenue 9th Floor New York NY NEW YORK 10017 Director Paul Kelly 750 Third Avenue 9th Floor New York NY NEW YORK 10017 Director Maged Shenouda 750 Third Avenue 9th Floor New York NY NEW YORK 10017 Director Biotechnology No Revenues 06b false 2017-09-28 false true true false 5000 Alexander Capital, LP 40077 None None 17 STATE STREET 5TH FLOOR NEW YORK NY NEW YORK 10004 AL ALABAMA CO COLORADO CT CONNECTICUT FL FLORIDA GA GEORGIA MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK PA PENNSYLVANIA RI RHODE ISLAND SC SOUTH CAROLINA TX TEXAS VA VIRGINIA false 6890000 6890000 0 false 65 584500 0 Not included in the sales commission amount is a non-accountable 1% allowance ($58,540) for expenses paid to the agent. The agent also received warrants to purchase 779,333 shares of common stock of the issuer. 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false RELMADA THERAPEUTICS, INC. /s/ Sergio Traversa Sergio Traversa CEO 2017-10-05